CD8A and non-small cell lung carcinoma: Specifically, higher levels of lymphocytes, including higher percentage and count of total T cells, percentage of Ki67+CD8+ T cells and natural killer (NK) cell count prior to treatment with the anti-PD-1 inhibitor budigalimab were associated with improved clinical response and longer PFS in a phase I trial that included 40 patients with advanced NSCLC [28].